Kirrhos Pharmaceuticals is focused on developing an orally available, small molecule inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a condition in which fat builds up in the liver as a result of obesity, diabetes and/or metabolic disease; it is distinct from other fatty liver diseases caused by alcohol abuse. If untreated, accumulation of fat causes excessive inflammation and scarring of the liver, and ultimately may lead to cirrhosis and/or liver cancer.
With the rise of obesity and diabetes, the incidence of NASH is increasing year over year. The National Institutes of Health estimate that 3-12% of American adults have NASH and the global market for NASH-related therapeutics is expected to reach $18.3 Billion by 2026 with an estimated 63% CAGR. Since there are currently no approved treatments for NASH, the opportunity is large, with several pharmaceutical companies actively seeking early stage drug assets.